gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients

Meeting Abstract

  • corresponding author presenting/speaker Andrea Tuettenberg - Johannes Gutenberg University Mainz, Deutschland
  • Christian Becker - Johannes Gutenberg University Mainz
  • Eva Huter - Rupprecht Karls University Heidelberg
  • Jürgen Knop - Johannes Gutenberg University Mainz
  • Alexander H. Enk - Rupprecht Karls University Heidelberg
  • Helmut Jonuleit - Johannes Gutenberg University Mainz

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO612

The electronic version of this article is the complete one and can be found online at:

Published: March 20, 2006

© 2006 Tuettenberg et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



A significant percentage of stage II melanoma patients (tumor thickness >1mm) remain at risk of tumor recurrence after primary tumor excision. In this study, we used tumor antigen-pulsed dendritic cells as an adjuvant for immunization of these “high risk” melanoma patients after resection of the primary tumor. A total of 13 patients were included and vaccinated six times every 14 days with autologous dendritic cells pulsed with a MelanA/MART-1 peptide in combination with a recall antigen. Antigen-specific immune responses were monitored before, during and up to one year after the last vaccination. The majority of patients exhibited increased recall antigen-specific CD4+ T cell responses upon vaccination. MelanA/MART-1-specific CD8+ T cells were expanded in 9/13 patients resulting in increased frequencies of memory cells in these patients. CD8+ T cells acquired the capacity to secrete IFN-g, to proliferate in culture in response to the tumor antigen used for vaccination and post vaccine samples contained.